Just days later doctors diagnosed him with a rare genetic disorder called Ornithine Transcarbamylase Deficiency (OTC). “I think the actual stats are about one in every 35,000 have a urea cycle ...
today announced that initial data from the Phase 1/2 OTC-HOPE clinical trial evaluating in vivo gene editing candidate ECUR-506 in neonatal onset ornithine transcarbamylase (OTC) deficiency will ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Vous recherchez des jeux simples ? Je vous propose trois chevaux à suivre ce mardi 4 mars sur l'hippodrome de Compiègne (R3).